USFDA issues warning letter to Divis Labs for Vizag unit
The United States Food and Drug Administration (USFDA) has issued warning letter for the company's Unit-II at Vishakhapatnam, Divis Laboratories said in a BSE filing.
DRUG MANUFACTURING
-
Warning letter: USFDA pulls up Sun Pharma for manufacturing issues at Dadra facility
USFDA further noted that the company's investigations of out-of-specification (OOS) results were inadequate because they lacked scientific rationale for root cause determinations.
-
Panel to examine if nutraceuticals can be produced within drug unit
-
India's Serum in talks on fill-finishing malaria vaccine in Ghana, official says
-
RePharma Summit sees a promising future for Indian Pharma Sector
-
Power of Cloud Utilization for the Pharmaceutical Industry
-
Tremendous scope for India-US cooperation in health technology and pharma, says expert
-
Govt taking measures to ramp up drug production: Official
-
We are focused on unlocking business value by working on manufacturing processes: Dilip Sawhney
-
No substitute for quality at low cost for growth-minded Indian pharma cos: David Keeling, McKinsey
Advertisement
More in DRUG MANUFACTURING
Advertisement
Get updates on your preferred social platform
Follow us for the latest news, insider access to events and more.
